Trial Profile

A Multicenter, Open-label, Expanded Access Study of KTE-X19 for the Treatment of Subjects With Relapsed/Refractory B-Cell Malignancies

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Dec 2024 According to a John Theurer Cancer Center media release, data from this trial will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024.
12 Dec 2023 Results of OS outcomes after 4 years in ZUMA-2 and the primary analysis of ZUMA-18, presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 According to a Kite pharma Media release, company announced result of four new analyses supporting the use of Tecartus in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia presented at ASH 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com